Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing small molecule therapeutics targeting fibrosis, cancer, inflammation, and related diseases. Its lead candidates include GB3226, a preclinical dual inhibitor of ENL-YEATS and FLT3 aimed at blood cancer indications such as acute myeloid leukemia and myeloproliferative neoplasms, and GB1211, an oral galectin-3 inhibitor for various oncology and liver disease applications. The company focuses on advancing innovative treatments that address unmet needs in hematologic malignancies and fibrotic conditions through precise molecular targeting. Damora Therapeutics, Inc. operates in the biopharmaceutical sector, contributing to the pipeline of novel therapies for severe diseases by leveraging expertise in inhibitor design and preclinical development. Founded in 2011 and headquartered in Copenhagen, Denmark, it plays a role in the global effort to improve patient outcomes in oncology and fibrosis through targeted small molecule approaches.